DK0728018T3 - Nye enzymer og prodrugs til ADEPT - Google Patents

Nye enzymer og prodrugs til ADEPT

Info

Publication number
DK0728018T3
DK0728018T3 DK95900827T DK95900827T DK0728018T3 DK 0728018 T3 DK0728018 T3 DK 0728018T3 DK 95900827 T DK95900827 T DK 95900827T DK 95900827 T DK95900827 T DK 95900827T DK 0728018 T3 DK0728018 T3 DK 0728018T3
Authority
DK
Denmark
Prior art keywords
adept
prodrugs
enzymes
new enzymes
nucleic acid
Prior art date
Application number
DK95900827T
Other languages
English (en)
Inventor
Gary Keith Smith
Michael Cory
Todd Andrew Blumenkopf
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0728018T3 publication Critical patent/DK0728018T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK95900827T 1993-11-12 1994-11-11 Nye enzymer og prodrugs til ADEPT DK0728018T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323429A GB9323429D0 (en) 1993-11-12 1993-11-12 Therapy
PCT/GB1994/002483 WO1995013095A2 (en) 1993-11-12 1994-11-11 Therapy

Publications (1)

Publication Number Publication Date
DK0728018T3 true DK0728018T3 (da) 2003-11-24

Family

ID=10745113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900827T DK0728018T3 (da) 1993-11-12 1994-11-11 Nye enzymer og prodrugs til ADEPT

Country Status (15)

Country Link
US (2) US6140100A (da)
EP (1) EP0728018B1 (da)
JP (1) JPH09507834A (da)
AT (1) ATE246516T1 (da)
AU (1) AU688412B2 (da)
CA (1) CA2176024A1 (da)
DE (1) DE69433015T2 (da)
DK (1) DK0728018T3 (da)
ES (1) ES2204935T3 (da)
GB (1) GB9323429D0 (da)
IL (1) IL111601A0 (da)
MY (1) MY114140A (da)
NZ (1) NZ276137A (da)
WO (1) WO1995013095A2 (da)
ZA (1) ZA948987B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB2309033B (en) * 1994-12-23 1999-06-02 Zeneca Ltd Chemical compounds
CN1095677C (zh) * 1994-12-23 2002-12-11 曾尼卡有限公司 化合物
CN1193278A (zh) * 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
AU2205499A (en) * 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
CA2390650A1 (en) 1999-11-12 2001-05-17 Lexicon Genetics Incorporated Novel human proteases and polynucleotides encoding the same
EP1343531A2 (en) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Conjugates of antibodies and anticancer drugs
SI1425001T1 (sl) 2001-09-14 2009-04-30 Glaxo Group Ltd Glaxo Welcome Fenetanolaminski derivati za zdravljenje respiratornih bolezni
ES2358730T3 (es) 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
EP1725250A2 (en) * 2004-02-18 2006-11-29 Frutarom Ltd. Method for the preparation of peptide-oligonucleotide conjugates
WO2006035008A1 (de) * 2004-09-27 2006-04-06 Merck Biosciences Ag Rekombinante carboxypeptidase b
CA2586334A1 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
EP2491788B1 (en) 2011-02-25 2015-12-23 Kraft Foods R & D, Inc. Food product with a moulded body
US9340504B2 (en) * 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
SG11201604993WA (en) * 2013-12-17 2016-07-28 Stella Pharma Corp A method for producing 2-fluoro-4-borono-l-phenylalanine, and precursor of 2-fluoro-4-borono-l-phenylalanine
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
WO2022272307A1 (en) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
WO1990007929A1 (en) * 1989-01-23 1990-07-26 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
MY114140A (en) 2002-08-30
ZA948987B (en) 1996-05-13
AU688412B2 (en) 1998-03-12
US6319702B1 (en) 2001-11-20
EP0728018A1 (en) 1996-08-28
IL111601A0 (en) 1995-01-24
CA2176024A1 (en) 1995-05-18
DE69433015T2 (de) 2004-06-09
US6140100A (en) 2000-10-31
AU8148894A (en) 1995-05-29
GB9323429D0 (en) 1994-01-05
ATE246516T1 (de) 2003-08-15
EP0728018B1 (en) 2003-08-06
NZ276137A (en) 1998-04-27
JPH09507834A (ja) 1997-08-12
DE69433015D1 (de) 2003-09-11
WO1995013095A3 (en) 1995-07-13
WO1995013095A2 (en) 1995-05-18
ES2204935T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
DK0728018T3 (da) Nye enzymer og prodrugs til ADEPT
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
DE69231745D1 (de) Gensequenzen kodierend für Flavonoid-Stoffwechselwegenzyme und deren Verwendung
EP1151085B8 (en) Nucleic acid molecules encoding alternansucrase
AU5753598A (en) Novel genes coding for amino acid deacetylases with specificity for N-acetyl-L-phosphinothricin, their isolation and use
DE69535543D1 (de) Für enzyme, die die fähigkeit besitzen lineare alpha 1,4-glucane in pflanzen, pilzen und mikroorganismen zu synthesieren, kodierende dna sequenzen
NO20021931L (no) L-pantolacton-hydrolase og en fremgangsmåte for fremstilling av D-pantolacton
GEP20032871B (en) Regulation of Quinolate Phosphoribosyl Transferase Expression
DE69331484T2 (de) N-Acetylglucosaminyl-Transferase, dafür kodierendes Gen, entsprechende Vektoren und transformierte Wirte und Herstellungsverfahren dafür
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
DE69521331T2 (de) Nukleinsäure-einbringungssystem
HU9502920D0 (en) New bacillus thuringiensis strains and their insecticidal proteins
BG101892A (en) Sugar-modified cytostatics
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
AU1682092A (en) Production of plants resistant to attacks of sclerotinia sclerotiorum by introducing a gene coding for an oxalate oxidase
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
DE69427990T2 (de) Tyrosinaseaktivator-tyrosinase-fusions-enzym
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
ATE262034T1 (de) Xylanasen, für diese kodierende gene und anwendungen derselben
IL136496A0 (en) Nucleotide sequences encoding the tomato light hypersensitive phenotype, encoded proteins and uses thereof
MX9709459A (es) Metodo para prolongar la expresion de un gen de interes usando moleculas de ctla4 solubles.
HUP0102540A2 (hu) Új angiotenzin-receptor, eljárás előállítására és alkalmazása